Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study

BACKGROUND: The increased risk of abacavir in cardiovascular disease (CVD) in HIV-infected patients is still being debated. Maraviroc, a CCR5 blocker, has been shown to decrease immune activation and monocyte infiltration in atherosclerotic plaques in murine experiments. Therefore, we examined the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Krikke, Maaike, Tesselaar, Kiki, Arends, Joop E., Drylewicz, Julia, Otto, Sigrid A., van Lelyveld, Steven F. L., Visseren, Frank J. L., Hoepelman, Andy I. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019971/
https://www.ncbi.nlm.nih.gov/pubmed/27300170
http://dx.doi.org/10.1007/s40121-016-0115-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019971/
https://www.ncbi.nlm.nih.gov/pubmed/27300170
http://dx.doi.org/10.1007/s40121-016-0115-0

Ejemplares similares